Repligen Corp

RGEN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
xFVLOCK|WtD?LOCK|!#<hTQCV

Repligen Earnings: Strong Start to the Year, Excellent Margin Expansion

Repligen reported year-over-year organic revenue growth of 11% and adjusted EBITDA margin of 20.6%, an expansion of 130 basis points. For 2026, management reiterated guidance for organic revenue growth of 9% to 13% and raised guidance for adjusted EBITDA margin by 30 basis points to 20.3 to 20.8%.

Sponsor Center